Form 4: Jasper Therapeutics CFO Herb Cross Granted 90,000 Stock Options with Long-Term Vesting

Jasper Therapeutics, Inc. (JSPR) Chief Financial Officer Herb Cross was granted 90,000 stock options with an exercise price of $6, vesting over four years, as disclosed in a recent SEC Form 4 filing.

Summary

• Herb Cross, Chief Financial Officer of Jasper Therapeutics, Inc. (JSPR), was granted 90,000 stock options.
• The stock options have an exercise price of $6.00 per share.
• The transaction date and the date the options become exercisable is June 4, 2025.
• The options are set to expire on June 4, 2035.
• The vesting schedule specifies that 1/4th of the shares (22,500 options) will vest on June 4, 2026.
• Following the initial vesting, 1/48th of the shares (1,875 options) will vest each month thereafter.
• Vesting is contingent upon Mr. Cross's continuous service to the Issuer on and through each applicable vesting date.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive like the CFO is generally a positive signal for retention and alignment of interests, indicating confidence in future performance. The long vesting period reinforces this. However, it is a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options to CFO Herb Cross aligns management's incentives with shareholder value creation, as the options gain value only if the stock price increases above the $6 exercise price.
• A long-term vesting schedule (over four years) encourages executive retention and commitment to the company's sustained performance and strategic goals.

Risks

• Potential future dilution of existing shareholder equity if the 90,000 stock options are exercised, which would increase the total number of outstanding shares.
• The value of the granted stock options is contingent on Jasper Therapeutics' stock price exceeding the $6 exercise price; if the stock underperforms, the options may not provide the intended incentive or financial benefit to the executive.

Future Outlook

The stock option grant with a long-term vesting schedule suggests a strategic intent to retain key management and align their long-term interests with the company's future growth and stock performance, indicating confidence in the company's long-term prospects.

Industry Context

This filing is a standard executive compensation disclosure common in the biotechnology or pharmaceutical industry, where stock options are a primary tool to attract, retain, and incentivize key personnel, particularly in companies focused on long-term research and development and clinical milestones.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if executive incentives lead to improved company performance and stock appreciation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale and confidence in the company's direction.

Next Steps

• Continued service of Herb Cross to Jasper Therapeutics, Inc. to ensure vesting of the granted stock options.
• Monitoring of JSPR's stock price relative to the $6 exercise price to assess the potential value of the options and their impact on executive incentives.

Key Dates

Recommendation

Keywords

Jasper Therapeutics, JSPR, SEC Form 4, Stock Options, Executive Compensation, Herb Cross, CFO, Beneficial Ownership, Equity Grant, Vesting Schedule